Luqa Pharmaceuticals Launches Strataderm® in China

Luqa Pharmaceuticals Launches Strataderm® in China

Shanghai, PR China – February 1st, 2013 Luqa Pharmaceuticals today announces that Strataderm® Gel is now available throughout China. Strataderm® is an innovative silicone gel recently approved by the State Food and Drug Administration (SFDA).

Strataderm® is a rapidly drying, non-sticky, transparent, silicone gel formulation for the treatment of scars, both old and new. Strataderm® has been developed using a new silicone polymer technology that is self drying without the use of Silicone Dioxide. Silicone gel is the only non-invasive scar treatment option for which evidence based recommendations have been made. The International Clinical Recommendations on Scar Management stated "silicone gel should be used as first line therapy in the initial management of scars and in the prevention of hypertrophic scars and keloids". Up to 94% of Chinese patients develop hypertrophic scars following median sternotomy incision and 41% of women develop a hypertrophic scar within 12 weeks of caesarean delivery. Strataderm® is one of the few clinically proven products for scar therapy are currently available in China.

More information about Strataderm® in China can be found here.

About Luqa
Luqa Pharmaceuticals is a China-based specialty pharmaceutical company with operations across Asia. We dedicate our talent to build a best in class portfolio of innovative products to meet the medical needs of the markets we work in. We are experts and are passionate about bringing products to market in record time, enhancing market access and commercialization excellence. Luqa's entrepreneurial culture combines international best practices and know-how with comprehensive, fast and flexible local strategies. Please visit us at

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.